Letter to the Editor: Pharmacokinetics of Lopinavir/Ritonavir in Hospitalized Patients with COVID-19 Not Requiring Critical Care

Abstract

Get full access to this article

View all access options for this article.

References

RECOV Collaborative Group

ERY

. 2020. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 396:1345–1352.

Mahdi

, Motyan

, Szojka

, et al. 2020. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2 main protease. Virol. J. 17:190.

Zhang

, Liu

, Cao

, et al. 2020. Comparative antiviral efficacy of viral protease inhibitors against the Novel SARS-CoV-2 in vitro. Virol. Sin. 35:776–784.

Gregoire

, Turnier

P.L

, Gaborit

B.J

, et al. 2020. Lopinavir, pharmacokinetics in COVID-19 patients. J. Antimicrob. Chemother. 75:2702–2704.

Schoergenhofer

, Jilma

, Karolyi

, et al. 2020. Pharmacokinetics of Lopinavir and ritonavir in patients hospitalised with Coronavirus Disease 2019 (COVID-19). Ann. Interv. Med. DOI: 10.7326/M20-1550.